AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist
Novo Nordisk has paid $60 million to partner Valo Health on a project that will apply the US start-up’s artificial intelligence-powered drug discovery engine to find new t
Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud
Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge
New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical "game changer
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh